Orphan Indications for CD19 Redirected Autologous T Cells

Infants With Very High Risk KMT2A B-ALL Clinical Trial

Official title: CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T Cells (CART19) for Orphan Indications of Pediatric B Cell Acute Lymphoblastic Leukemia (B ALL)

Status Recruiting

Clinical Trial Summary

This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort C), and in patients with central nervous system (CNS) relapse who did not receive cranial radiation (XRT) or bone marrow transplantation (BMT) (Cohort D).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Infants With Very High Risk KMT2A B-ALL
• Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
• Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL
• Recurrence

• NCT number: NCT04276870
• Study type: Interventional
• Source: Children's Hospital of Philadelphia
• Contact: Amanda DiNofia, MD, PhD
• Phone: 215-590-5476
• Email: DiNofiaA@chop.edu
• Status: Recruiting
• Phase: Phase 2
• Start date: March 12, 2020
• Completion date: March 10, 2037